Brind.

AbbVie submitted an application for the Skyrizi induction regimen to the European Medicines Agency.

1 report, 1 independent Updated Aug 29

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

AbbVie European Medicines Agency

Keep exploring

The entities involved

AbbVie
pharmaceutical company
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
European Medicines Agency
highest regulatory authority on medicines in the European Union
- IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.Mon 14:18
- Both the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Fri 23:04

Coverage

Newest first; wire copies grouped

Aug 29yahoo.com